A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Colorectal Cancer Clinical Trial

Official title:

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03872947
• Other study ID #: 950P1V02
• Status: Recruiting
• Phase: Phase 1
• Start date: April 26, 2019
• Est. completion date: March 2025

Study information

• Verified date: May 2024
• Source: Toray Industries, Inc
• Contact: Vicki Bauernschub, BSN, RN
• Phone: 602 358 8324
• Email: vbauernschub[@]td2inc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.

Description:

This study is an open-label, Phase 1b study evaluating TRK-950 in combination with 1) FOLFIRI or 2) Gemcitabine / Cisplatin or 3) Gemcitabine / Carboplatin or 4) Ramucirumab/Paclitaxel or 5) PD1 inhibitors (Nivolumab or Pembrolizumab) or 6) Imiquimod Cream for subcutaneous lesions 7) Bevacizumab 8) Gemcitabine / Carboplatin / Bevacizumab, 9)PLD, 10) Carboplatin / PLD / Bevacizumab or 11) Paclitaxel in Patients with Selected Advanced Solid Tumors. The objectives of this study are to determine the safety, tolerability, MTD, recommended Phase 2 dose (RP2D), PK, and preliminary anti-tumor activity of TRK-950 when used in combination with other treatment regimens.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 187
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed solid malignancy for which the following treatment regimens are warranted:

• Arm A. Colorectal Cancer with no prior history of treatment with Irinotecan alone or in combination: FOLFIRI as standard of care

• Arm B. Cholangiocarcinoma, Bladder Cancer with no prior history of treatment with Gemcitabine alone or in combination: Gemcitabine / Cisplatin as standard of care

• Arm C. Ovarian Cancer who have relapsed at least 6 or more months after completion of a previous platinum-based therapy and have no prior history of treatment with gemcitabine alone or in combination: Gemcitabine / Carboplatin as standard of care

• Arm D. Gastric Cancer including Gastroesophageal Junction with no prior history of treatment with Ramucirumab, Paclitaxel or any Taxane class drug: Ramucirumab / Paclitaxel as standard of care

• Arm E. Solid Tumors: Eligible for PD1 Inhibitor (Nivolumab or Pembrolizumab) monotherapy as standard of care according to the approved drug label by the relevant regulatory authority

• Arm F. Locally advanced or metastatic disease in a cancer with at least one palpable subcutaneous malignant lesion (= 2 cm in diameter) for treatment with TRK-950 and Imiquimod cream (US Sites Only)

• Arm G. Renal Cell Carcinoma with no prior history of treatment with Bevacizumab alone or in combination: Bevacizumab for use in a fourth line or later treatment

• Arm H. Melanoma patients who progressed while taking Nivolumab, Pembrolizumab, or Ipilimumab, within the last 6 months prior to cycle 1 day 1

• Arm J. Colorectal Cancer patients who progressed on FOLFIRI or any other Irinotecan-containing therapy regimen within the last 6 months prior to cycle 1 day 1

• Arm K. (US Sites Only). Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer with = 2 prior treatment lines who have recurred > 6 months after most recent platinum-based chemotherapy and who are eligible for gemcitabine, carboplatin, and Bevacizumab as standard of care for dosing of TRK-950

• Arm O. Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer with = 5 prior treatment regimens, as defined below and who are eligible for topotecan or pegylated liposomal doxorubicin as standard of care for dosing of TRK-950

• Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response, and then progressed between 3 months and less than or equal to 6 months after the last date of platinum.

• Patients who have received 2 to 5 lines of prior therapy must have received at least 4 cycles of platinum and then progressed within 6 months after the date of the last dose of platinum.

• Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy

• Arm Q. Gastric Cancer including GEJ cancer with only 1 prior treatment regimen, which recurred during or within 4 months after frontline treatment, and no prior history of treatment with Ramucirumab, Paclitaxel or any Taxane class drug for metastatic disease: eligible to receive Ramucirumab/Paclitaxel as standard of care

• Arm R. Clear cell renal cell carcinoma with no prior history of treatment with Bevacizumab alone or in combination: Bevacizumab for use in a fourth line or later treatment.

• Arm S. Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer with = 2 prior treatment lines who have recurred > 182 days after most recent platinum-based chemotherapy and who are eligible for carboplatin, PLD, and bevacizumab as standard of care

• The histological subtypes of the carcinoma that qualify for enrollment include serous adenocarcinoma, endometrioid adenocarcinoma, carcinosarcoma of the ovary, or adenocarcinoma not otherwise specified (NOS)

• Patients with or without the breast cancer susceptibility 1/2 (BRCA1/2) mutations are eligible, provided that patients with the BRCA1/2 mutations have previously received PARP inhibitor treatment

• Arm T. Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer with = 5 prior treatment regimens, or as defined below, and who are eligible for paclitaxel as standard of care

• Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (complete response/remission (CR) or partial response/remission (PR), and then progressed between 90 days to less than 183 days after the last date of platinum.

• Patients who have received multiple lines of platinum therapy must have progressed on the latest platinum, or within 183 days after the date of the last dose of the latest platinum

• Patients with or without the BRCA1/2 mutations are eligible, provided that patients with the BRCA1/2 mutations have previously received PARP inhibitor treatment

• Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy

• The histological subtypes of the carcinoma that qualify for enrollment include serous adenocarcinoma, endometrioid adenocarcinoma, carcinosarcoma of the ovary, or adenocarcinoma not otherwise specified (NOS)

• Primary or metastatic tumors measurable per RECIST v1.1 on CT scan or by calipers (subcutaneous lesions)

• Karnofsky performance of =70

• Life expectancy of at least 3 months

• Age = 18 years

• Signed, written IRB-approved informed consent

Exclusion Criteria:

• Laboratory values or medications that are contraindicated in the selected standard of care treatment regimens

• New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG

• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Prophylactic antibiotics are acceptable.

• Pregnant or nursing women

• Treatment with radiation therapy within 2 weeks, or treatment with surgery, chemotherapy, immunotherapy, targeted therapy or investigational therapy within four weeks prior to initiation of study treatment (6 weeks for nitrosoureas or mitomycin C, and 2 weeks or 5 half-lives whichever is longer for TKIs).

• Unwillingness or inability to comply with procedures required in this protocol

• Known active infection with HIV, hepatitis B, hepatitis C

• Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor

• Patients who are currently receiving any other investigational agent

• Any contraindicated condition or drug which would make the patient ineligible for the respective treatment regimen that is to be used in combination with TRK-950 (for example, autoimmune disorders for nivolumab or pembrolizumab treatment) as described in the Full Prescribing Information

Related Conditions & MeSH terms

• Bladder Cancer
• Carcinoma, Ovarian Epithelial
• Carcinoma, Renal Cell
• Cholangiocarcinoma
• Colorectal Cancer
• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Gastric Cancer
• Melanoma
• Ovarian Cancer
• Ovarian Neoplasms
• Palpable Subcutaneous Malignant Lesions
• Primary Peritoneal Cancer
• Renal Cell Carcinoma
• Solid Tumor

Intervention

Biological:
• TRK-950
10 mg/kg administered intravenously over 60 minutes (weekly)
• TRK-950
5 mg/kg administered intravenously over 60 minutes (weekly)
• TRK-950
Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)

Drug:
• Irinotecan
Intravenously over 30 - 90 minutes
• Leucovorin
Intravenously over 30 - 90 minutes
• 5-FU
Intravenously bolus and intravenously for two days
• Gemcitabine
Intravenously over 30 minutes
• Cisplatin
Intravenously over 60 minutes
• Carboplatin
Intravenously per package insert
• Ramucirumab
Intravenously over 60 minutes
• Paclitaxel
Intravenously
• Nivolumab
Intravenously over 30 minutes
• Pembrolizumab
Intravenously over 30 minutes
• Imiquimod Cream
Topically
• Bevacizumab
Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses
• PLD
Intravenously over 60 minutes

Locations

Country	Name	City	State
France	Centre Léon Bérard	Lyon
United States	Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center	Dallas	Texas
United States	Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center)	Eugene	Oregon
United States	Texas Oncology - Downtown Fort Worth Cancer Center	Fort Worth	Texas
United States	Virginia Cancer Specialists, PC	Leesburg	Virginia
United States	USC Norris Comprehensive Cancer Center	Los Angeles	California
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Atlantic Health System	Morristown	New Jersey
United States	Ochsner Clinic Foundation	New Orleans	Louisiana
United States	Perlmutter Cancer Center at NYU Langone	New York	New York
United States	HOAG Memorial Hospital Presbyterian	Newport	California
United States	Northwest Cancer Specialists	Portland	Oregon
United States	HonorHealth Research Institute	Scottsdale	Arizona
United States	AOA-HOPE	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Toray Industries, Inc

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0		through study completion, an average of 1 year
Primary	Frequency of patients experiencing adverse events of special interest (AESIs)		through study completion, an average of 1 year
Primary	Blood pressure	mmHg	through study completion, an average of 1 year
Primary	Heart rate	bpm	through study completion, an average of 1 year
Primary	Respiratory rate	bpm	through study completion, an average of 1 year
Primary	Temperature	°F or °C	through study completion, an average of 1 year
Primary	Weight	lbs/kg	through study completion, an average of 1 year
Primary	Height	inches/cm	through study completion, an average of 1 year
Primary	Performance status using Karnofsky performance status criteria		through study completion, an average of 1 year
Primary	QTc interval determined from 12-lead Electrocardiogram	msec	through study completion, an average of 1 year
Primary	QRS interval determined from 12-lead Electrocardiogram	msec	through study completion, an average of 1 year
Primary	Frequency of patients with laboratory abnormalities (Complete Blood Count, Coagulation, Urinalysis and Serum Chemistry)		through study completion, an average of 1 year
Secondary	Overall response rate (ORR)		through study completion, an average of 1 year
Secondary	Disease Control Rate (DCR)		through study completion, an average of 1 year
Secondary	Serum concentration of TRK-950		through study completion, an average of 1 year
Secondary	Plasma concentration of Gemcitabine for the first six patients in Arm K		At the beginning of Cycle 1 and Cycle 4 (each cycle is 21 days)
Secondary	Plasma concentration of Carboplatin for the first six patients in Arm K		At the beginning of Cycle 1 and Cycle 4 (each cycle is 21 days)
Secondary	Serum concentration of Bevacizumab for the first six patients in Arm K		At the beginning of Cycle 1, Cycle 2, Cycle 4 and Cycle 5 (each cycle is 21 days)
Secondary	Plasma concentration of PLD for the first six patients in Arm O		At the beginning and middle of Cycle 1 and Cycle 3 (each cycle is 28 days)
Secondary	Serum concentration of Ramucirumab for the first six patients in Arm Q		At the beginning and middle of Cycle 1 and Cycle 4 (each cycle is 28 days)
Secondary	Plasma concentration of Paclitaxel for the first six patients in Arm Q		At the beginning of Cycle 1 and Cycle 4 (each cycle is 28 days)
Secondary	Serum concentration of Bevacizumab for the first six patients in Arm R		At the beginning and middle of Cycle 1 and Cycle 4 (each cycle is 28 days)